Ikoma, Japan

Takazumi Taniguchi

USPTO Granted Patents = 4 

 

Average Co-Inventor Count = 2.7

ph-index = 1


Company Filing History:

goldMedal4 out of 282 
 
Santen Pharmaceutical Co., Ltd.
 patents
silverMedal1 out of 832,912 
Other
 patents
where one patent can have more than one assignee

Years Active: 2013-2025

Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: Takazumi Taniguchi: Innovator in Ocular Therapeutics

Introduction

Takazumi Taniguchi is a notable inventor based in Ikoma, Japan. He has made significant contributions to the field of ocular therapeutics, particularly in the treatment of glaucoma and ocular hypertension. With a total of 4 patents to his name, Taniguchi's work has the potential to enhance patient care and treatment outcomes.

Latest Patents

One of Taniguchi's latest patents involves a medicament comprising a combination of sepetaprost and a Rho-associated coiled-coil containing protein kinase inhibitor. This innovative combination serves as a prophylactic or therapeutic agent for glaucoma or ocular hypertension. The unique formulation enhances the intraocular pressure-lowering action compared to the use of each drug alone. The administration of this medicament can be done either concomitantly or as a combination drug, showcasing its versatility in treatment options.

Career Highlights

Throughout his career, Takazumi Taniguchi has worked with Santen Pharmaceutical Co., Ltd., where he has contributed to the development of advanced therapeutic solutions. His expertise in ocular pharmacology has positioned him as a key figure in the industry, driving forward innovative treatments for eye conditions.

Collaborations

Taniguchi has collaborated with notable colleagues, including Yasuko Yamamoto and Takahiro Akaishi. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and advancements in ocular therapeutics.

Conclusion

In summary, Takazumi Taniguchi is a distinguished inventor whose work in ocular therapeutics has the potential to significantly impact the treatment of glaucoma and ocular hypertension. His innovative approaches and collaborations continue to pave the way for advancements in this critical field.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…